EWA
CTMX icon

EP Wealth Advisors’s CytomX Therapeutics CTMX Stock Holding History

EP Wealth Advisors’s Portfolio CTMX Stock Details CTMX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-10,432
Closed -$12.3K – 1255
2024
Q3 		$12.3K Buy
+10,432
New +$13.3K ﹤0.01% 1175

Other funds holding CTMX

TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return
SSA
Schonfeld Strategic Advisors New York $14.2B AUM 37.17% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

EP Wealth Advisors's CTMX Position: Q4 2024 in Review

EP Wealth Advisors sold out of CytomX Therapeutics (CTMX) in Q4 2024, closing a stake of 10,432 shares — an estimated $12.3K sold.

EP Wealth Advisors first reported a position in CTMX in Q3 2024 and held it in 1 quarter. The position peaked at $12.3K in Q3 2024. 70 funds tracked by Wall St. Rank hold CTMX as of Q4 2024.

  • EP Wealth Advisors reported no remaining CytomX Therapeutics position as of Q4 2024 after selling out during the quarter.
  • EP Wealth Advisors sold 10,432 CytomX Therapeutics shares in Q4 2024, an estimated $12.3K.
  • EP Wealth Advisors first reported a position in CytomX Therapeutics in Q3 2024 and held it in 1 quarter.
  • EP Wealth Advisors's CytomX Therapeutics position peaked at $12.3K in Q3 2024.
  • 70 funds tracked by Wall St. Rank held CytomX Therapeutics as of Q4 2024.

Based on EP Wealth Advisors's 13F filing for Q4 2024, filed 14 Feb 2025.